Employees: 11 (2023.0)Legal category: 5785Size: PMECreation date: 1997-05-02 (29 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: NANTES (44300), Loire-Atlantique
SELAS PHARMACIE DU ROND POINT DE RENNES : revenue, balance sheet and financial ratios
SELAS PHARMACIE DU ROND POINT DE RENNES is a French company
founded 29 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in NANTES (44300),
this company of category PME
shows in 2024 a revenue of 2.2 M€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - SELAS PHARMACIE DU ROND POINT DE RENNES (SIREN 412147589)
Indicator
2025
2024
2023
2020
2019
2018
2017
Revenue
N/C
2 176 631 €
N/C
N/C
N/C
1 367 458 €
1 315 856 €
Net income
33 813 €
43 615 €
45 650 €
617 854 €
88 439 €
78 890 €
66 626 €
EBITDA
N/C
66 461 €
N/C
N/C
N/C
98 387 €
80 685 €
Net margin
N/C
2.0%
N/C
N/C
N/C
5.8%
5.1%
Revenue and income statement
In 2025, SELAS PHARMACIE DU ROND POINT DE RENNES generates positive net income of 34 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2017-2025: 67 k€ -> 34 k€.
Net income (2025)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
33 813 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 53%. Debt remains under control: the company retains capacity to raise new debt if needed. Financial autonomy (= Equity / Total assets x 100) reaches 53%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
Debt ratio (2025)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
53.062%
Financial autonomy (2025)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
53.005%
Asset age ratio (2025)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Solvency indicators evolution SELAS PHARMACIE DU ROND POINT DE RENNES
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2017
2018
2019
2020
2023
2024
2025
Debt ratio
4.489
17.44
27.575
53.246
85.023
68.96
53.062
Financial autonomy
68.961
70.991
67.244
57.927
45.003
50.751
53.005
Repayment capacity
0.541
2.23
None
None
None
8.149
None
Cash flow / Revenue
4.725%
4.738%
None%
None%
None%
2.869%
None%
Sector positioning
Debt ratio
53.062025
2023
2024
2025
Q1: 13.7
Med: 49.79
Q3: 129.09
Average
In 2025, the debt ratio of SELAS PHARMACIE DU ROND P... (53.06) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
Financial autonomy
53.01%2025
2023
2024
2025
Q1: 33.42%
Med: 53.72%
Q3: 72.08%
Average
In 2025, the financial autonomy of SELAS PHARMACIE DU ROND P... (53.0%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
Repayment capacity
8.15 years2024
2024
Q1: 0.52 years
Med: 3.19 years
Q3: 7.6 years
Average
In 2024, the repayment capacity of SELAS PHARMACIE DU ROND P... (8.15) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 258.62. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2025)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
258.618
Liquidity indicators evolution SELAS PHARMACIE DU ROND POINT DE RENNES
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2017
2018
2019
2020
2023
2024
2025
Liquidity ratio
100.118
200.288
245.587
518.883
306.315
346.854
258.618
Interest coverage
4.343
2.482
None
None
None
5.033
None
Sector positioning
Liquidity ratio
258.622025
2023
2024
2025
Q1: 131.03
Med: 182.25
Q3: 258.64
Excellent
In 2025, the liquidity ratio of SELAS PHARMACIE DU ROND P... (258.62) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.
Interest coverage
5.03x2024
2024
Q1: 0.0x
Med: 2.35x
Q3: 7.73x
Good
In 2024, the interest coverage of SELAS PHARMACIE DU ROND P... (5.0x) ranks above the median of the sector. This ratio indicates how many times operating income covers interest expenses. This comfortable position offers an appreciable safety margin.
Working capital requirement (WCR) and payment terms
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.
Operating WCR (2025)
?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released Positive = financing needed
0 €
Customer credit (2025)
?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good 45-60j : Average > 60j : Long
0 j
Supplier credit (2025)
?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow
0 j
Inventory turnover (2025)
?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover
0 j
WCR and payment terms evolution SELAS PHARMACIE DU ROND POINT DE RENNES
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2017
2018
2019
2020
2023
2024
2025
Operating WCR
96 492 €
298 858 €
0 €
0 €
0 €
512 988 €
0 €
Inventory turnover (days)
31
31
0
0
0
27
0
Customer payment term (days)
6
7
0
0
0
6
0
Supplier payment term (days)
46
57
0
0
0
34
0
Positioning of SELAS PHARMACIE DU ROND POINT DE RENNES in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 277 transactions of similar company sales
in 2025,
the value of SELAS PHARMACIE DU ROND POINT DE RENNES is estimated at
537 123 €
(range 364 494€ - 842 820€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2025
277 transactions
364k€537k€842k€
537 123 €Range: 364 494€ - 842 820€
NAF 5 année 2025
Valuation method used
Net Income Multiple
33 813 €
×
15.9x
=537 124 €
Range: 364 495€ - 842 821€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 277 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare SELAS PHARMACIE DU ROND POINT DE RENNES with other companies in the same sector:
Frequently asked questions about SELAS PHARMACIE DU ROND POINT DE RENNES
What is the revenue of SELAS PHARMACIE DU ROND POINT DE RENNES ?
The revenue of SELAS PHARMACIE DU ROND POINT DE RENNES in 2024 is 2.2 M€.
Is SELAS PHARMACIE DU ROND POINT DE RENNES profitable?
Yes, SELAS PHARMACIE DU ROND POINT DE RENNES generated a net profit of 34 k€ in 2025.
Where is the headquarters of SELAS PHARMACIE DU ROND POINT DE RENNES ?
The headquarters of SELAS PHARMACIE DU ROND POINT DE RENNES is located in NANTES (44300), in the department Loire-Atlantique.
Where to find the tax return of SELAS PHARMACIE DU ROND POINT DE RENNES ?
The tax return of SELAS PHARMACIE DU ROND POINT DE RENNES is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does SELAS PHARMACIE DU ROND POINT DE RENNES operate?
SELAS PHARMACIE DU ROND POINT DE RENNES operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart